November 7, 2023
FTLD digital biomarker publication and 2023 CNS Summit
We are excited to share a recent paper from our digital biomarker study in frontotemporal lobar degeneration (FTLD) (ClinicalTrials.gov NCT05956834), published in Parkinsonism & Related Disorders.
The paper, titled "Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson's disease" showcases the potential of BioDigit SpeechTM to distinguish between Parkinson's disease and progressive supranuclear palsy (PSP) - a severe and rapidly progressive FTLD syndrome that lacks effective treatment and leads to a rapid onset of dementia, disability, and death. You can freely access and download the paper.
Dr Vaziri will present the findings of this study during the Innovation Showcase at the 2023 CNS Summit this week on Friday, November 10.
Furthermore, BioSensics will be presenting three posters at the Summit related to our work in developing digital health technologies for neurological disorders:
Poster #2: "Continuous Monitoring of Upper Limb Function in Neurological Disorders". Read more about PAMSys ULMTM.
About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.
BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of their solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.
BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.